Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: winzer5 who wrote (13864)	12/17/2004 5:25:19 PM
From: Cal Gary	Read Replies (1) \| Respond to of 14101

Its either REK and bandits wanting to stage a come back next AGM buying up cheap 29 cent shares OR Pfizer finds heart risk with its painkiller drug Celebrex Dec. 17, 2004 Provided by: Associated Press A new study finds increased risk of heart problems with taking painkiller drug Celebrex. (AP Photo/Mary Altaffer) NEW YORK (AP) - Pfizer Inc. says it has found an increased risk of heart problems with patients taking its painkiller Celebrex, a drug that is in the same class as Vioxx, pulled from the market in September because of safety concerns. Pfizer announced Friday that it found the increased risk in one of two long-term cancer prevention trials, while the other trial showed no increased risk. The company was conducting the trials as part of an effort to find a new application for the drug. The news sent the stock of the giant pharmaceutical maker plunging in early trading on the New York Stock Exchange, where its shares were down $4.37, or 15 per cent, at $24.61 US. Celebrex is currently approved for use in the United States for the treatment of arthritis and pain. Earlier this month, the U.S. Food and Drug Administration said it was adding a warning to the labels of another Pfizer drug, Bextra, warning of potential heart problems associated with the use of that drug in people who have recently had heart bypass surgery. Bextra, Celebrex and Vioxx are all in a class of pain drugs called cox-2 inhibitors. The drugs have become popular because of their effectiveness in treating the pain of arthritis and other ailments. Merck & Co. pulled Vioxx from the market Sept. 30 after a study indicated it doubled the risk of heart attacks and stroke when taken for longer than 18 months. Studies done five years ago - when Celebrex and Vioxx were approved - suggest the same mechanism that inhibits inflammation and makes the drugs easier on the stomach also blocks a substance that prevents heart problems, scientists have said. chealth.canoe.ca